• br Conclusion There have been multiple clinical

  2024-12-17

  

  Conclusion There have been multiple clinical trials and pre-clinical studies that have tested the utility of 5ARIs in treating prostate disease, as summarized in Fig. 1. Inhibiting androgen action through the use of finasteride and dutasteride has been established as a valuable resource for physi

• Overexpression of SMAD and SMAD strongly enhanced luciferase

  2024-12-17

  

  Overexpression of SMAD3 and SMAD4 strongly enhanced luciferase activity of the new pN10 reporter gene construct which was further reinforced by addition of TGFβ. Serial mutations of SBE-1 and SBE-2 led to a slight loss in 5-LO promoter inducibility. The data demonstrate that the two SBEs within the

• However although in vitro studies in heterologous systems ha

  2024-12-17

  

  However, although in vitro studies in heterologous systems have provided very important indications of potential novel pharmacology, the studies with endogenous receptors in native tissues are essential to provide evidence for GPCR heteromerization in vivo and to confirm its physiological relevance.

• br The human CYP A

  2024-12-17

  

  The human CYP17A1 gene is located on chromosome 10q24.3 (1) and spans 6.6 kb, which contain eight exons (2) and 1.6 kb of coding region. From this gene, the same 2.1-kb mRNA species is transcribed in both the adrenals and gonads (3), which yields a 57-kDa microsomal cytochrome P450c17 enzyme (CYP1

• br Autophagy in hemorrhagic stroke About of all strokes

  2024-12-17

  

  Autophagy in hemorrhagic stroke About 87% of all strokes cases are ischemic, the rest being hemorrhagic. ICH and SAH are the two major categories of hemorrhagic strokes (Bruder et al., 2014). Both types of stroke are associated with a high mortality and morbidity rate. The corresponding animal mo

• Receptors containing an x y

  2024-12-16

  

  Receptors containing an αx/γy subunit interface, where x=1, 2, 3, 5 and y=1–3, form a high-affinity binding site for benzodiazepines (Figure 1A), for the later developed Z-drugs of different chemotypes, and for a large number of chemically distinct research compounds 17, 18 (Box 1 for examples). For

• It was reported that oral

  2024-12-16

  

  It was reported that oral administration of CSZ to C57BL/6J mice significantly improved spatial learning and memory, and prevented Aβ-induced immunoresponse in Aβ25-35-injected mice. However, post-treatment with CSZ after Aβ25-35 administration, when Aβ was already accumulated, did not prevent Aβ-in

• Interestingly we noticed that LPS exposure was associated wi

  2024-12-16

  

  Interestingly, we noticed that LPS exposure was associated with decreased phosphorylation of AMPK and increased phosphorylation of p70S6K1, suggesting that AMPK inactivation and the subsequent mTOR activation might be involved in the development of LPS-induced inflammation. On the other side, treatm

• Although it is not known if CP AMPAR

  2024-12-16

  

  Although it is not known if CP-AMPAR regulation is required for LTD, our previous characterization of AKAP150ΔPIX knockin mice that are selectively deficient in CaN anchoring, due to disruption of a PxIxIT-type CaN docking motif, provided important insights. We found that AKAP-CaN signaling dephosph

• To date LOX is the only

  2024-12-16

  

  To date, 12-LOX is the only LOX isoform that has been identified in the platelet [17]. Interestingly, while 12-LOX is highly expressed (∼14000 molecules/platelet) in the platelet, 12(R)-LOX expression is absent in the hematopoietic lineage and has therefore not been reported to be expressed in plate

• br Development of lorlatinib from crizotinib to

  2024-12-16

  

  Development of lorlatinib from crizotinib (1) to a clinical candidate (6) Xalkori (1, PF-02341066, crizotinib), was the first-in-class ALK inhibitor approved by the Unites States Food and Drug Administration (FDA) in 2011 as a first-line treatment for ALK+- NSCLC patients. This section describes

• Aldose reductase ALR EC the first enzyme in the polyol

  2024-12-16

  

  Aldose reductase (ALR2, EC1.1.1.21), the first enzyme in the polyol pathway, is a monomeric oxidoreductase that catalyses the NADPH-dependent reduction of a wide variety of carbonyl compounds, especially glucose. In this metabolism pathway, glucose is firstly reduced to sorbitol catalyzed by ALR2 wi

• br Acknowledgements br Introduction Diabetic

  2024-12-16

  

  Acknowledgements Introduction Diabetic complications are responsible for increased morbidity and mortality of diabetic patients. Increased flow of cantharidin through the polyol pathway under conditions of hyperglycemia contributes to the development of diabetic complications. Aldose reductase

• br ABCA is a sterol responsive gene The first evidence

  2024-12-16

  

  ABCA2 is a sterol-responsive gene The first evidence to demonstrate that ABCA2 expression responded to sterol loading was provided in an experiment involving monocyte to macrophage differentiation in vitro. Upon sterol loading with enzymatically degraded LDL (eLDL), ABCA2 expression increased onl

• G has been shown to participate

  2024-12-16

  

  Gβγ has been shown to participate in various MT-dependent processes such as cell growth and differentiation [15,[21], [22], [23], [24], [25], [26]]. G-protein β-subunit anti-sense oligonucleotides have been shown to inhibit cell proliferation and cause disorganization of the mitotic spindle in mamma

14207 records 37/948 page Previous Next First page 上5页 3637383940 下5页 Last page